Early-Stage Biotech's AI Advantage Is A Window That Closes. Sol Babani And Derk Arts On How To Use It

Most AI guidance in clinical development focuses on the technology itself. The real challenge is operational strategy. In a candid discussion between Symbiosis Advisors founder Sol Babani and Castor CEO Derk Arts, MD, PhD, the conversation moves beyond AI hype to examine what early-stage biotech teams actually need to succeed in regulated clinical environments. The session explores where current FDA AI guidance is helpful, where it falls short, and why waiting for perfect regulatory clarity is the wrong approach.

Instead of retrofitting AI onto legacy workflows, the speakers argue that emerging biotech companies have a rare opportunity to build modern, AI-enabled clinical operations from the ground up. Topics include human-in-the-loop oversight, validation strategy, 21 CFR Part 11 compliance, and the critical build-versus-buy decision facing sponsors today. For biotech leaders planning their first studies or evaluating AI adoption, this discussion offers a practical framework for building compliant, scalable AI strategies before legacy processes become barriers.